TAKEDA BELGIUM
The computed 12-month bankruptcy probability of TAKEDA BELGIUM is 0.2% (very low). The 2025 annual accounts show equity of €52.61M and a net result of €4.17M. Equity is growing by ~12.8% per year across the filed fiscal years. Its solvency ranks better than 77% of 187 sector peers (fiscal year 2025). The company has been active since 1945 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €52.61M |
| Net result | €4.17M |
| Staff (FTE) | 78.6 |
| Better than sector | 77% |
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 63.6% | 41.5% | |
| Net result | €4.17M | €159k | |
| Equity | €52.61M | €1.10M | |
| Staff costs | €16.40M | €760k | |
| Employees (FTE) | 78.6 | 10.0 |
Show 13 other metrics
| Fiscal year | 2025 |
|---|---|
| Deposit | volledig |
| Revenue | €201.45M |
| EBITDA | €7.22M |
| Net profit | €4.17M |
| Cash flow | €5.00M |
| Staff costs | €16.40M |
| Income taxes | €1.66M |
| Dividends | - |
| Total assets | €82.74M |
| Equity | €52.61M |
| Debt | €30.02M |
| of which ≤ 1y | €30.02M |
| of which > 1y | - |
| Working capital | €48.89M |
| Employees (FTE) | 78.6 |
| 2025 | |
|---|---|
| Current ratio | 2.63 |
| Quick ratio | 1.36 |
| Working capital ratio | 59.1% |
| Solvency | 63.6% |
| Debt / equity | 0.57 |
| Long-term debt ratio | - |
| Interest coverage | 12.28 |
| Gross margin | 27.8% |
| Net margin | 2.1% |
| ROA | 5.0% |
| ROE | 7.9% |
| EBITDA margin | 3.6% |
| Days sales outstanding | 74d |
| Days payable outstanding | 21d |
| Inventory turnover | 3.82 |
| Days inventory (DSI) | 95d |
Full annual accounts (26 line items)
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €82.74M |
| Fixed assets | 21/28 | €3.83M |
| Intangible fixed assets | 21 | €3.13M |
| Tangible fixed assets | 22/27 | €475k |
| Financial fixed assets | 28 | €227k |
| Current assets | 29/58 | €78.91M |
| Stocks & contracts in progress | 3 | €38.02M |
| Amounts receivable within one year | 40/41 | €40.64M |
| Cash & bank | 54/58 | €88k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €82.74M |
| Equity | 10/15 | €52.61M |
| Contributions / capital | 10/11 | €5.58M |
| Reserves | 13 | €1.09M |
| Accumulated profits (losses) | 14 | €45.94M |
| Provisions & deferred taxes | 16 | €113k |
| Amounts payable | 17/49 | €30.02M |
| Amounts payable within one year | 42/48 | €30.02M |
| Trade debts payable within one year | 44 | €8.45M |
| Income statement | ||
| Turnover | 70 | €201.45M |
| Operating result | 9901 | €6.39M |
| Financial income | 75 | €35k |
| Financial charges | 65 | €588k |
| Result before taxes | 9903 | €5.84M |
| Income taxes | 67/77 | €1.66M |
| Net result for the period | 9904 | €4.17M |
| Result to be appropriated | 9905 | €4.17M |
-
Current25-09-2025 → present
3 events
- 25-09-2025 Mandate renewed· Director
- 01-01-2025 Resigned· Managing director
- 07-03-2022 Appointed· Managing director
-
Current01-09-2024 → present
2 events
- 01-01-2025 Appointed· Managing director
- 01-09-2024 Appointed· Director
-
Current01-11-2023 → present
-
Current07-03-2022 → present
Historic, not recently confirmed (4)
-
Takeda International Holding GmbHLegal entityManager· perm. rep.: STOSSEL PeterState Gazette act 20016764 (29-01-2020)Not recently confirmedlast confirmed in an act from 2020
-
Not recently confirmedlast confirmed in an act from 2014
-
Not recently confirmedlast confirmed in an act from 2014
-
Not recently confirmedlast confirmed in an act from 2013
Former directors (6)
-
Former- → 27-06-2024
-
Former- → 01-11-2023
-
Former08-01-2019 → 07-03-2022
2 events
- 07-03-2022 Resigned· Director
- 08-01-2019 Appointed· Manager
-
Former- → 19-12-2019
2 events
- 19-12-2019 Resigned· Manager
- 30-01-2013 Resigned· Director
-
Former- → 08-01-2019
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| KPMG Bedrijfsrevisoren CVBACurrent Statutory auditor · represented by Axel Jorion |
- | 04-12-2020 → present |
Show 3 earlier auditors
| Klynveld, Peat, Marwick, Goerdeler - Réviseurs d'Entreprises Company auditor · represented by Olivier Declercq succeeded by KPMG Réviseurs d'Entreprises in 2015 |
- | 20-12-2011 → 31-03-2015 |
| KPMG Bedrijfsrevisoren Burg. CVBA Statutory auditor · represented by Axel Jorion succeeded by KPMG Bedrijfsrevisoren CVBA in 2020 |
- | 03-11-2017 → 04-12-2020 |
| KPMG Réviseurs d'Entreprises Statutory auditor · represented by Olivier DECLERCQ succeeded by KPMG Bedrijfsrevisoren Burg. CVBA in 2017 |
- | 31-03-2015 → 03-11-2017 |
| NACE primary | Groothandel in farmaceutische en medische artikelen(46460) |
| Legal form | Public limited company(014) |
| Incorporation | 11-06-1945 |
| Status | Active |
| Postal code | 1930 |
Each band states what its claims rest on. A board seat is influence over the board, not ownership. Court mandates (receiver, interim administrator) and liquidation mandates do not link companies and are therefore absent here; they belong under Directors & mandates.
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 23094D0081/00D003 | Flanders | 6,456 m² | 1 · 1,500 m² | 34.9 m · 10 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
18-12-2025 Change in the board of directors
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "NV"
}
}07-11-2025 Paul DE PROFT reappointed as director
- Paul DE PROFT, Bestuurder
Technical details
{
"events": [
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Paul DE PROFT",
"address": null,
"birth_date": null
},
"effective_date": "2025-09-25",
"evidence_quote": "De algemene vergadering beslist om het mandaat van Paul DE PROFT, woonstkeuze doende op de zetel van de Vennootschap, als bestuurder te hernieuwen voor een periode van 6 jaar."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "NV"
}
}22-07-2025 Board meeting · Statute amendment · General meeting · Officer appointment
- Publication: 22/07/2025 · Algemene Vereniging van de Geneesmiddelenindustrie
- Filing: 11/07/2025 · Algemene Vereniging van de Geneesmiddelenindustrie
- Board meeting: 23/04/2025 · Algemene Vereniging van de Geneesmiddelenindustrie
- Statute amendment: wijziging delegatiereglement dagelijks bestuur · Algemene Vereniging van de Geneesmiddelenindustrie
- General meeting: 11/06/2025 · Algemene Vereniging van de Geneesmiddelenindustrie
- Officer appointment: role: bestuurder, start_date: 2025-06-11 · Almirall N.V.
- Officer appointment: role: bestuurder, start_date: 2025-06-11 · Novo Nordisk Pharma N.V.
- Officer appointment: role: bestuurder, start_date: 2025-06-11 · Takeda Belgium N.V.
- Officer reappointment: role: bestuurder, start_date: 2025-06-11 · Amgen N.V.
- Officer reappointment: role: bestuurder, start_date: 2025-06-11 · MSD Belgium N.V.
- Officer reappointment: role: bestuurder, start_date: 2025-06-11 · Roche N.V.
- Officer reappointment: role: bestuurder, start_date: 2025-06-11 · UCB Pharma N.V.
- Officer resignation: role: bestuurder, end_date: 2025-06-11 · Vertex Pharmaceuticals (Netherlands) BV
- Permanent representative: start_date: 16/05/2025 · Paul Lacante
- Permanent representative · Gregory Paton
- Permanent representative · Axel De Muyt
- Permanent representative · Bruno Rabilier
Technical details
{
"facts": [
{
"date": "2025-07-22",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad -22/07/2025 - Annexes du Moniteur belge",
"value": "22/07/2025",
"object": null,
"subject": "e1"
},
{
"date": "2025-07-11",
"type": "filing",
"quote": "neergelegd/ontvangen op 114 JULI 2025",
"value": "11/07/2025",
"object": null,
"subject": "e1"
},
{
"date": "2025-04-23",
"type": "board_meeting",
"quote": "VERGADERING VAN DE RAAD VAN BESTUUR VAN 23 APRIL 2025",
"value": "23/04/2025",
"object": null,
"subject": "e1"
},
{
"type": "statute_amendment",
"quote": "Onderwerp akte: Benoeming bestuurders - wijziging delegatiereglement dagelijks bestuur",
"value": "wijziging delegatiereglement dagelijks bestuur",
"object": null,
"subject": "e1"
},
{
"date": "2025-06-11",
"type": "general_meeting",
"quote": "GEWONE ALGEMENE VERGADERING VAN 11 JUNI 2025",
"value": "11/06/2025",
"object": null,
"subject": "e1"
},
{
"date": "2025-06-11",
"type": "officer_appointment",
"quote": "Benoeming van: Almirall N.V.",
"value": {
"role": "bestuurder",
"start_date": "2025-06-11"
},
"object": null,
"subject": "e2",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "11/06/2025"
}
},
{
"date": "2025-06-11",
"type": "officer_appointment",
"quote": "Benoeming van: Novo Nordisk Pharma N.V.",
"value": {
"role": "bestuurder",
"start_date": "2025-06-11"
},
"object": null,
"subject": "e3",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "11/06/2025"
}
},
{
"date": "2025-06-11",
"type": "officer_appointment",
"quote": "Benoeming van: Takeda Belgium N.V.",
"value": {
"role": "bestuurder",
"start_date": "2025-06-11"
},
"object": null,
"subject": "e4",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "11/06/2025"
}
},
{
"date": "2025-06-11",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 1. Amgen N.V.",
"value": {
"role": "bestuurder",
"start_date": "2025-06-11"
},
"object": null,
"subject": "e5",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "11/06/2025"
}
},
{
"date": "2025-06-11",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 2. MSD Belgium N.V.",
"value": {
"role": "bestuurder",
"start_date": "2025-06-11"
},
"object": null,
"subject": "e6",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "11/06/2025"
}
},
{
"date": "2025-06-11",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 3. Roche N.V.",
"value": {
"role": "bestuurder",
"start_date": "2025-06-11"
},
"object": null,
"subject": "e7",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "11/06/2025"
}
},
{
"date": "2025-06-11",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 4. UCB Pharma N.V.",
"value": {
"role": "bestuurder",
"start_date": "2025-06-11"
},
"object": null,
"subject": "e8",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "11/06/2025"
}
},
{
"type": "officer_resignation",
"quote": "Ontslag van: 1. Vertex Pharmaceuticals (Netherlands) BV",
"value": {
"role": "bestuurder",
"end_date": "2025-06-11"
},
"object": null,
"subject": "e9",
"_value_raw": {
"role": "bestuurder",
"reason": "ontslag",
"end_date": "11/06/2025"
}
},
{
"date": "2025-05-16",
"type": "permanent_representative",
"quote": "Bristol-Myers Squibb Belgium N.V. ... heeft als nieuwe vaste vertegenwoordiger vanaf 16/05/2025 de heer Paul Lacante",
"value": {
"start_date": "16/05/2025"
},
"object": "e10",
"subject": "e11"
},
{
"type": "permanent_representative",
"quote": "Almirall N.V. ... heeft als vaste vertegenwoordiger de heer Gregory Paton",
"value": {},
"object": "e2",
"subject": "e13"
},
{
"type": "permanent_representative",
"quote": "Novo Nordisk Pharma N.V. ... heeft als vaste vertegenwoordiger de heer Axel De Muyt",
"value": {},
"object": "e3",
"subject": "e14"
},
{
"type": "permanent_representative",
"quote": "Takeda Belgium N.V. ... heeft als vaste vertegenwoordiger de heer Bruno Rabilier",
"value": {},
"object": "e4",
"subject": "e15"
}
],
"act_meta": {
"outcome": "clean",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 9714,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "company",
"name": "Algemene Vereniging van de Geneesmiddelenindustrie",
"attrs": {
"seat": "Kantersteen 47, 1000 Brussel",
"legal_form": "Vereniging zonder Winstoogmerk",
"short_name": "AVGI"
}
},
{
"id": "e2",
"kbo": "0403.090.131",
"kind": "company",
"name": "Almirall N.V.",
"attrs": {
"seat": "Lenneke Marelaan 4, 1932 Sint-Stevens-Woluwe"
}
},
{
"id": "e3",
"kbo": "0414.695.586",
"kind": "company",
"name": "Novo Nordisk Pharma N.V.",
"attrs": {
"seat": "Alfons Gossetlaan 32E/202, 1702 Groot-Bijgaarden"
}
},
{
"id": "e4",
"kbo": "0403.054.202",
"kind": "company",
"name": "Takeda Belgium N.V.",
"attrs": {
"seat": "Leonardo Da Vincilaan 7, 1930 Zaventem"
}
},
{
"id": "e5",
"kbo": "0439.652.401",
"kind": "company",
"name": "Amgen N.V.",
"attrs": {
"seat": "Telecomlaan 5-7, 1831 Diegem"
}
},
{
"id": "e6",
"kbo": "0406.820.770",
"kind": "company",
"name": "MSD Belgium N.V.",
"attrs": {
"seat": "Vorstlaan 25, 1170 Watermaal-Bosvoorde"
}
},
{
"id": "e7",
"kbo": "0403.088.151",
"kind": "company",
"name": "Roche N.V.",
"attrs": {
"seat": "Dantestraat 75, 1070 Anderlecht"
}
},
{
"id": "e8",
"kbo": "0403.096.168",
"kind": "company",
"name": "UCB Pharma N.V.",
"attrs": {
"seat": "Researchdreef 60, 1070 Anderlecht"
}
},
{
"id": "e9",
"kbo": "0666.408.905",
"kind": "company",
"name": "Vertex Pharmaceuticals (Netherlands) BV",
"attrs": {
"seat": "Leidsevaart 20, NL - 2013 HA Haarlem"
}
},
{
"id": "e10",
"kbo": "0403.075.184",
"kind": "company",
"name": "Bristol-Myers Squibb Belgium N.V.",
"attrs": {}
},
{
"id": "e11",
"kbo": null,
"kind": "person",
"name": "Paul Lacante",
"attrs": {}
},
{
"id": "e12",
"kbo": null,
"kind": "person",
"name": "Sally McNab",
"attrs": {}
},
{
"id": "e13",
"kbo": null,
"kind": "person",
"name": "Gregory Paton",
"attrs": {}
},
{
"id": "e14",
"kbo": null,
"kind": "person",
"name": "Axel De Muyt",
"attrs": {}
},
{
"id": "e15",
"kbo": null,
"kind": "person",
"name": "Bruno Rabilier",
"attrs": {}
},
{
"id": "e16",
"kbo": null,
"kind": "company",
"name": "Facing BV",
"attrs": {}
},
{
"id": "e17",
"kbo": null,
"kind": "person",
"name": "Caroline Ven",
"attrs": {}
}
]
}16-01-2025 1 director appointed, 1 resigning
- Bruno Rabilier, Gedelegeerd bestuurder
- Paul de Proft, Gedelegeerd bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Paul de Proft",
"address": null,
"birth_date": null
},
"effective_date": "2025-01-01",
"evidence_quote": "De raad van bestuur heeft op unanieme wijze besloten: 1. De machten van dagelijks bestuur die in het verleden werden toegekend door de Vennootschap aan de heer Paul de Proft op datum van 7 maart 2022, zoals bekendgemaakt in de Bijlagen bij het Belgisch Staatsblad van 11 april 2022 onder nummer 22046"
},
{
"kind": "director_in",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Bruno Rabilier",
"address": null,
"birth_date": null
},
"effective_date": "2025-01-01",
"evidence_quote": "2. Overeenkomstig artikel 7:121 WVV, de machten van dagelijks bestuur toe te kennen aan de heer Bruno Rabilier, met Franse nationaliteit en keuze van woonplaats doende op de zetel van de Vennootschap, te Da Vincilaan 7, 1930 Zaventem, Belgi\u00EB, met ingang van 1 januari 2025, en dit tot de machten word"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "NV"
}
}30-09-2024 Bruno Rabilier appointed as director
- Bruno Rabilier, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Bruno Rabilier",
"address": null,
"birth_date": null
},
"effective_date": "2024-09-01",
"evidence_quote": "De Aandeelhouder besluit om heer Bruno Rabilier, houdende de franse nationaliteit, keuze van woonplaats doende op de zetel van de Vennootschap, te benoemen als bestuurder van de Vennootschap, met ingang van 1 september 2024 tot aan de jaarlijkse algemene aandeelhoudersvergadering te houden in 2029"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "NV"
}
}23-08-2024 General meeting · Board meeting · Officer appointment · Officer reappointment
- Publication: 23/08/2024 · Algemene Vereniging van de Geneesmiddelenindustrie
- Filing: 19/06/2024 · Algemene Vereniging van de Geneesmiddelenindustrie
- General meeting: 13/03/2024 · Algemene Vereniging van de Geneesmiddelenindustrie
- Board meeting: 15/05/2024 · Algemene Vereniging van de Geneesmiddelenindustrie
- Officer appointment: role: bestuurder, start_date: 2024-03-13 · Bayer N.V.
- Officer reappointment: role: bestuurder, start_date: 2024-03-13 · AbbVie N.V.
- Officer reappointment: role: bestuurder, start_date: 2024-03-13 · Eli Lilly Benelux N.V.
- Officer reappointment: role: bestuurder, start_date: 2024-03-13 · Pfizer N.V.
- Officer reappointment: role: bestuurder, start_date: 2024-03-13 · GlaxoSmithKline Pharmaceuticals N.V.
- Officer resignation: date: 2024-03-13, role: bestuurder · Takeda Belgium N.V.
- Officer appointment: role: ondervoorzitter van de Raad van Bestuur, start_date: 2024-05-15 · An Van Gerven
- Permanent representative · Werner De Prins
- Permanent representative: start_date: 24/05/2024 · Bart Vermeulen
- Permanent representative: start_date: 14/06/2024 · Niels Hessmann
- Statute amendment · Algemene Vereniging van de Geneesmiddelenindustrie
Technical details
{
"facts": [
{
"date": "2024-08-23",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 23/08/2024",
"value": "23/08/2024",
"object": null,
"subject": "e1"
},
{
"date": null,
"type": "filing",
"quote": "neergelegd/ontvangen op 19 JUNI 2024 ter griffie van de Nederlandstalige ondernemingsrechtbank Brussel",
"value": "19/06/2024",
"object": null,
"subject": "e1",
"date_suspect": "2024-06-19"
},
{
"date": "2024-03-13",
"type": "general_meeting",
"quote": "BUITENGEWONE ALGEMENE VERGADERING VAN 13 MAART 2024",
"value": "13/03/2024",
"object": null,
"subject": "e1"
},
{
"date": "2024-05-15",
"type": "board_meeting",
"quote": "VERGADERING VAN DE RAAD VAN BESTUUR VAN 15 MEI 2024",
"value": "15/05/2024",
"object": null,
"subject": "e1"
},
{
"date": "2024-03-13",
"type": "officer_appointment",
"quote": "Benoeming van: Bayer N.V.",
"value": {
"role": "bestuurder",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e2",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 1. AbbVie N.V.",
"value": {
"role": "bestuurder",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e3",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 2. Eli Lilly Benelux N.V.",
"value": {
"role": "bestuurder",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e4",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 3. Pfizer N.V.",
"value": {
"role": "bestuurder",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e5",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 4.GlaxoSmithKline Pharmaceuticals N.V.",
"value": {
"role": "bestuurder",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e6",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_resignation",
"quote": "Ontslag van: 1. Takeda Belgium N.V.",
"value": {
"date": "2024-03-13",
"role": "bestuurder"
},
"object": "e1",
"subject": "e7",
"_value_raw": {
"date": "13/03/2024",
"role": "bestuurder"
}
},
{
"date": "2024-05-15",
"type": "officer_appointment",
"quote": "Op de Raad van Bestuur van 15 mei 2024 werd mevrouw An Van Gerven tot ondervoorzitter van de Raad van Bestuur benoemd.",
"value": {
"role": "ondervoorzitter van de Raad van Bestuur",
"start_date": "2024-05-15"
},
"object": "e1",
"subject": "e8",
"_value_raw": {
"role": "ondervoorzitter van de Raad van Bestuur",
"term": null,
"start_date": "15/05/2024"
}
},
{
"type": "permanent_representative",
"quote": "Bayer N.V. (BE 0404.754.571) heeft als vaste vertegenwoordiger de heer Werner De Prins.",
"value": null,
"object": "e2",
"subject": "e12"
},
{
"date": "2024-05-24",
"type": "permanent_representative",
"quote": "Sanofi Belgium N.V. (BE 0464.435.901) heeft als nieuwe vaste vertegenwoordiger vanaf 24/05/2024 de heer Bart Vermeulen in opvolging van de heer Johan Heylen.",
"value": {
"start_date": "24/05/2024"
},
"object": "e9",
"subject": "e10"
},
{
"date": "2024-06-14",
"type": "permanent_representative",
"quote": "Bayer N.V. (BE 0404.754.571) heeft als nieuwe vaste vertegenwoordiger vanaf 14/06/2024 de heer Niels Hessmann in opvolging van de heer Werner De Prins.",
"value": {
"start_date": "14/06/2024"
},
"object": "e2",
"subject": "e13"
},
{
"type": "statute_amendment",
"quote": "De voorgestelde wijzigingen aan de statuten werden goedgekeurd door de Buitengewone Algemene Vergadering van 13 maart 2024",
"value": null,
"object": null,
"subject": "e1"
}
],
"act_meta": {
"outcome": "clean",
"postfix": [
"filing date 2024-06-19 outside [pub-60d, pub] -\u003E nulled (garbled stamp?)"
],
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 27430,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "company",
"name": "Algemene Vereniging van de Geneesmiddelenindustrie",
"attrs": {
"seat": "Terhulpsesteenweg 166, 1170 Brussel",
"legal_form": "Vereniging zonder Winstoogmerk",
"short_name": "AVGI"
}
},
{
"id": "e2",
"kbo": "0404.754.571",
"kind": "company",
"name": "Bayer N.V.",
"attrs": {
"seat": "J.E. Mommaertslaan 14, 1831 Diegem"
}
},
{
"id": "e3",
"kbo": "0845.096.860",
"kind": "company",
"name": "AbbVie N.V.",
"attrs": {
"seat": "avenue Einstein 14, 1300 Wavre"
}
},
{
"id": "e4",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux N.V.",
"attrs": {
"seat": "Markiesstraat 1, 1000 Brussel"
}
},
{
"id": "e5",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer N.V.",
"attrs": {
"seat": "Pleinlaan 17, 1050 Elsene"
}
},
{
"id": "e6",
"kbo": "0403.066.474",
"kind": "company",
"name": "GlaxoSmithKline Pharmaceuticals N.V.",
"attrs": {
"seat": "avenue Fleming 20, 1300 Wavre"
}
},
{
"id": "e7",
"kbo": "0403.054.202",
"kind": "company",
"name": "Takeda Belgium N.V.",
"attrs": {
"seat": "Leonardo Da Vincilaan 7, 1930 Zaventem"
}
},
{
"id": "e8",
"kbo": null,
"kind": "person",
"name": "An Van Gerven",
"attrs": {}
},
{
"id": "e9",
"kbo": "0464.435.901",
"kind": "company",
"name": "Sanofi Belgium N.V.",
"attrs": {}
},
{
"id": "e10",
"kbo": null,
"kind": "person",
"name": "Bart Vermeulen",
"attrs": {}
},
{
"id": "e11",
"kbo": null,
"kind": "person",
"name": "Johan Heylen",
"attrs": {}
},
{
"id": "e12",
"kbo": null,
"kind": "person",
"name": "Werner De Prins",
"attrs": {}
},
{
"id": "e13",
"kbo": null,
"kind": "person",
"name": "Niels Hessmann",
"attrs": {}
},
{
"id": "e14",
"kbo": null,
"kind": "person",
"name": "Caroline Ven",
"attrs": {}
}
]
}23-08-2024 Act object · General meeting · Officer appointment · Officer reappointment
- Act object: Nomination administrateurs - nomination vice-présidente Conseil d'administration - modifications aux statuts - nouveaux représentants permanents des administrateurs · Association Générale de l'Industrie du Médicament
- Publication: 23/08/2024 · Association Générale de l'Industrie du Médicament
- Filing: 19/06/2024 · Association Générale de l'Industrie du Médicament
- General meeting: 13/03/2024 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: administrateur, start_date: 2024-03-13 · Bayer S.A.
- Officer reappointment: role: administrateur, start_date: 2024-03-13 · AbbVie S.A.
- Officer reappointment: role: administrateur, start_date: 2024-03-13 · Eli Lilly Benelux S.A.
- Officer reappointment: role: administrateur, start_date: 2024-03-13 · Pfizer S.A.
- Officer reappointment: role: administrateur, start_date: 2024-03-13 · GlaxoSmithKline Pharmaceuticals S.A.
- Officer resignation: date: 2024-03-13, role: administrateur · Takeda Belgium S.A.
- Statute amendment: Modifications aux statuts approuvées par l'AGE du 13 mars 2024 (articles 2, 5, 9, 12, 16, 28 et dispositions transitoires) · Association Générale de l'Industrie du Médicament
- Board meeting: 15/05/2024 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: Vice-Présidente, start_date: 2024-05-15 · An Van Gerven
- Permanent representative · Werner De Prins
- Permanent representative: start_date: 24/05/2024 · Bart Vermeulen
- Permanent representative: start_date: 14/06/2024 · Niels Hessmann
Technical details
{
"facts": [
{
"type": "act_object",
"quote": "Objet de l\u0027acte: Nomination administrateurs - nomination vice-pr\u00E9sidente Conseil d\u0027administration - modifications aux statuts - nouveaux repr\u00E9sentants permanents des administrateurs",
"value": "Nomination administrateurs - nomination vice-pr\u00E9sidente Conseil d\u0027administration - modifications aux statuts - nouveaux repr\u00E9sentants permanents des administrateurs",
"object": null,
"subject": "e1"
},
{
"date": "2024-08-23",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 23/08/2024 - Annexes du Moniteur belge",
"value": "23/08/2024",
"object": null,
"subject": "e1"
},
{
"date": null,
"type": "filing",
"quote": "neergelegd/ontvangen op 19 JUNI 2024",
"value": "19/06/2024",
"object": null,
"subject": "e1",
"date_suspect": "2024-06-19"
},
{
"date": "2024-03-13",
"type": "general_meeting",
"quote": "ASSEMBLEE GENERALE EXTRAORDINAIRE DU 13 MARS 2024",
"value": "13/03/2024",
"object": null,
"subject": "e1"
},
{
"date": "2024-03-13",
"type": "officer_appointment",
"quote": "Nomination de : Bayer S.A.",
"value": {
"role": "administrateur",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e2",
"_value_raw": {
"role": "administrateur",
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 1. AbbVie S.A.",
"value": {
"role": "administrateur",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e3",
"_value_raw": {
"role": "administrateur",
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: ... 2. Eli Lilly Benelux S.A.",
"value": {
"role": "administrateur",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e4",
"_value_raw": {
"role": "administrateur",
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: ... 3. Pfizer S.A.",
"value": {
"role": "administrateur",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e5",
"_value_raw": {
"role": "administrateur",
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: ... 4.GlaxoSmithKline Pharmaceuticals S.A.",
"value": {
"role": "administrateur",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e6",
"_value_raw": {
"role": "administrateur",
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_resignation",
"quote": "D\u00E9mission de: 1. Takeda Belgium S.A.",
"value": {
"date": "2024-03-13",
"role": "administrateur"
},
"object": "e1",
"subject": "e7",
"_value_raw": {
"date": "13/03/2024",
"role": "administrateur"
}
},
{
"date": "2024-03-13",
"type": "statute_amendment",
"quote": "Les modifications propos\u00E9es aux statuts ont \u00E9t\u00E9 approuv\u00E9es par l\u0027Assembl\u00E9e G\u00E9n\u00E9rale Extraordinaire du 13 mars 2024",
"value": "Modifications aux statuts approuv\u00E9es par l\u0027AGE du 13 mars 2024 (articles 2, 5, 9, 12, 16, 28 et dispositions transitoires)",
"object": null,
"subject": "e1"
},
{
"date": "2024-05-15",
"type": "board_meeting",
"quote": "REUNION DU CONSEIL D\u0027ADMINISTRATION DU 15 MAI 2024",
"value": "15/05/2024",
"object": null,
"subject": "e1"
},
{
"date": "2024-05-15",
"type": "officer_appointment",
"quote": "Lors du Conseil d\u0027administration du 15 mai 2024, Madame An Van Gerven a \u00E9t\u00E9 d\u00E9sign\u00E9e comme Vice-Pr\u00E9sidente.",
"value": {
"role": "Vice-Pr\u00E9sidente",
"start_date": "2024-05-15"
},
"object": "e1",
"subject": "e8",
"_value_raw": {
"role": "Vice-Pr\u00E9sidente",
"start_date": "15/05/2024"
}
},
{
"type": "permanent_representative",
"quote": "Bayer S.A. (BE 0404.754.571) a d\u00E9sign\u00E9 comme repr\u00E9sentant permanent Monsieur Wemer De Prins.",
"value": {
"start_date": null
},
"object": "e2",
"subject": "e9"
},
{
"date": "2024-05-24",
"type": "permanent_representative",
"quote": "Sanofi Belgium S.A. (BE 0464.435.901) a d\u00E9sign\u00E9 comme nouveau repr\u00E9sentant permanent \u00E0 partir du 24/05/2024 Monsieur Bart Vermeulen, succ\u00E9dant \u00E0 Monsieur Johan Heylen.",
"value": {
"start_date": "24/05/2024"
},
"object": "e10",
"subject": "e11"
},
{
"date": "2024-06-14",
"type": "permanent_representative",
"quote": "Bayer S.A. (BE 0404.754.571) a d\u00E9sign\u00E9 comme nouveau repr\u00E9sentant permanent \u00E0 partir du 14/06/2024 Monsieur Niels Hessmann, succ\u00E9dant \u00E0 Monsieur Werner De Prins.",
"value": {
"start_date": "14/06/2024"
},
"object": "e2",
"subject": "e13"
}
],
"act_meta": {
"outcome": "clean",
"postfix": [
"filing date 2024-06-19 outside [pub-60d, pub] -\u003E nulled (garbled stamp?)"
],
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 28008,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "org",
"name": "Association G\u00E9n\u00E9rale de l\u0027Industrie du M\u00E9dicament",
"attrs": {
"seat": "chauss\u00E9e de La Hulpe 166, 1170 Bruxelles",
"legal_form": "Association sans But Lucratif",
"short_name": "AGIM"
}
},
{
"id": "e2",
"kbo": "0404.754.571",
"kind": "company",
"name": "Bayer S.A.",
"attrs": {
"seat": "J..E. Mommaertslaan 14, 1831 Diegem"
}
},
{
"id": "e3",
"kbo": "0845.096.860",
"kind": "company",
"name": "AbbVie S.A.",
"attrs": {
"seat": "avenue Einstein 14, 1300 Wavre"
}
},
{
"id": "e4",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux S.A.",
"attrs": {
"seat": "rue du Marquis 1, 1000 Bruxelles"
}
},
{
"id": "e5",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer S.A.",
"attrs": {
"seat": "Boulevard de la Plaine 17, 1050 Ixelles"
}
},
{
"id": "e6",
"kbo": "0403.066.474",
"kind": "company",
"name": "GlaxoSmithKline Pharmaceuticals S.A.",
"attrs": {
"seat": "avenue Fleming 20, 1300 Wavre"
}
},
{
"id": "e7",
"kbo": "0403.054.202",
"kind": "company",
"name": "Takeda Belgium S.A.",
"attrs": {
"seat": "Leonardo Da Vincilaan 7, 1930 Zaventem"
}
},
{
"id": "e8",
"kbo": null,
"kind": "person",
"name": "An Van Gerven",
"attrs": {}
},
{
"id": "e9",
"kbo": null,
"kind": "person",
"name": "Werner De Prins",
"attrs": {}
},
{
"id": "e10",
"kbo": "0464.435.901",
"kind": "company",
"name": "Sanofi Belgium S.A.",
"attrs": {}
},
{
"id": "e11",
"kbo": null,
"kind": "person",
"name": "Bart Vermeulen",
"attrs": {}
},
{
"id": "e12",
"kbo": null,
"kind": "person",
"name": "Johan Heylen",
"attrs": {}
},
{
"id": "e13",
"kbo": null,
"kind": "person",
"name": "Niels Hessmann",
"attrs": {}
},
{
"id": "e14",
"kbo": null,
"kind": "person",
"name": "Caroline Ven",
"attrs": {
"role": "CEO, charg\u00E9 de la gestion journali\u00E8re"
}
}
]
}25-07-2024 Michael Nesraliah resigns as director
- Michael Nesraliah, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Michael Nesraliah",
"address": null,
"birth_date": null
},
"effective_date": "2024-06-27",
"evidence_quote": "De Aandeelhouder neemt kennis van en aanvaardt, voor zover als nodig, het ontslag van de heer Michael Nesraliah ais bestuurder van de Vennootschap, met ingang van 27 juni 2024."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "NV"
}
}22-11-2023 1 director appointed, 1 resigning
- Aline Vandecappelle, Bestuurder
- Elke Pittomvils, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Elke Pittomvils",
"address": null,
"birth_date": null
},
"effective_date": "2023-11-01",
"evidence_quote": "De Aandeelhouder neemt kennis van en aanvaardt, voor zoveel als nodig, het ontslag van mevrouw Elke Pittomvils als bestuurder van de Vennootschap, met ingang van 1 november 2023."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Aline Vandecappelle",
"address": null,
"birth_date": null
},
"effective_date": "2023-11-01",
"evidence_quote": "De Aandeelhouder besluit om mevrouw Aline Vandecappelle, houdende de Belgische nationaliteit, keuze van woonplaats doende op de zetel van de Vennootschap, te benoemen als bestuurder van de Vennootschap, met ingang van 1 november 2023 en voor een termijn van 6 jaar, tot aan de algemene aandeelhouders"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "NV"
}
}31-10-2023 Axel Jorion reappointed as statutory auditor
- Axel Jorion, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_renew",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Axel Jorion",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0403054202",
"name": "KPMG Bedrijfsrevisoren BV",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "De Aandeelhouder besluit KPMG Bedrijfsrevisoren BV, met zetel te Luchthaven Brussel Nationaal 1K, 1930 Zaventem, Belgi\u00EB, vertegenwoordigd door de heer Axel Jorion, bedrijfsrevisor, te herbenoemen als commissaris van de Vennootschap voor een duur van drie (3) jaar"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "NV"
}
}07-12-2022 Permanent representative · Board meeting · Officer appointment
- Filing: 2022-11-28 · Algemene Vereniging van de Geneesmiddelenindustrie
- Permanent representative: start_date: 2022-08-01 · Michael Nesrallah
- Permanent representative: start_date: 2022-11-01 · An Van Gerven
- Board meeting: 2022-10-19 · Algemene Vereniging van de Geneesmiddelenindustrie
- Officer appointment: role: Voorzitter van de Raad van Bestuur, start_date: 2022-10-19 · Frédéric Clais
- Board meeting: 2022-11-16 · Algemene Vereniging van de Geneesmiddelenindustrie
- Officer appointment: role: Ondervoorzitter van de Raad van Bestuur, start_date: 2022-11-16 · An Van Gerven
Technical details
{
"facts": [
{
"date": "2022-11-28",
"type": "filing",
"quote": "neergelegd/enwangen op 28 NOV. 2022",
"value": "2022-11-28",
"object": null,
"subject": "e1"
},
{
"date": "2022-08-01",
"type": "permanent_representative",
"quote": "Takeda Belgium N.V. ... heeft als nieuwe vaste vertegenwoordiger vanaf 01/08/2022 de heer Michael Nesrallah",
"value": {
"start_date": "2022-08-01"
},
"object": "e2",
"subject": "e3"
},
{
"date": "2022-11-01",
"type": "permanent_representative",
"quote": "Pfizer N.V. ... heeft als nieuwe vaste vertegenwoordiger vanaf 01/11/2022 mevrouw An Van Gerven",
"value": {
"start_date": "2022-11-01"
},
"object": "e4",
"subject": "e5"
},
{
"date": "2022-10-19",
"type": "board_meeting",
"quote": "VERGADERING VAN DE RAAD VAN BESTUUR VAN 19 OKTOBER 2022",
"value": "2022-10-19",
"object": null,
"subject": "e1"
},
{
"date": "2022-10-19",
"type": "officer_appointment",
"quote": "Op de Raad van Bestuur van 19 oktober 2022 werd de heer Fr\u00E9d\u00E9ric Clais tot voorzitter van de Raad van Bestuur benoemd.",
"value": {
"role": "Voorzitter van de Raad van Bestuur",
"start_date": "2022-10-19"
},
"object": "e1",
"subject": "e6"
},
{
"date": "2022-11-16",
"type": "board_meeting",
"quote": "VERGADERING VAN DE RAAD VAN BESTUUR VAN 16 NOVEMBER 2022",
"value": "2022-11-16",
"object": null,
"subject": "e1"
},
{
"date": "2022-11-16",
"type": "officer_appointment",
"quote": "Op de Raad van Bestuur van 16 november 2022 werd mevrouw An Van Gerven tot ondervoorzitter van de Raad van Bestuur benoemd.",
"value": {
"role": "Ondervoorzitter van de Raad van Bestuur",
"start_date": "2022-11-16"
},
"object": "e1",
"subject": "e5"
}
],
"act_meta": {
"outcome": "corrected",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1912,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "company",
"name": "Algemene Vereniging van de Geneesmiddelenindustrie",
"attrs": {
"seat": "Terhulpsesteenweg 166, 1170 Brussel",
"legal_form": "Vereniging zonder Winstoogmerk",
"short_name": "AVGI"
}
},
{
"id": "e2",
"kbo": "0403.054.202",
"kind": "company",
"name": "Takeda Belgium N.V.",
"attrs": {}
},
{
"id": "e3",
"kbo": null,
"kind": "person",
"name": "Michael Nesrallah",
"attrs": {
"address": "Eikenlaan 63, 1180 Ukkel",
"birth_date": "1978-11-11",
"birth_place": "Ottawa (Canada)"
}
},
{
"id": "e4",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer N.V.",
"attrs": {}
},
{
"id": "e5",
"kbo": null,
"kind": "person",
"name": "An Van Gerven",
"attrs": {
"address": "Vinkenbosstraat 30, 3053 Haasrode",
"birth_date": "1975-06-10",
"birth_place": "Leuven"
}
},
{
"id": "e6",
"kbo": null,
"kind": "person",
"name": "Fr\u00E9d\u00E9ric Clais",
"attrs": {}
}
]
}07-12-2022 Act object · Permanent representative · Board meeting · Officer appointment
- Act object: Nouveaux représentants permanents des administrateurs - Nomination président et vice-président · Association Générale de l'Industrie du Médicament
- Filing: 2022-11-28 · Association Générale de l'Industrie du Médicament
- Permanent representative: start_date: 2022-08-01 · Michael Nesrallah
- Permanent representative: start_date: 2022-11-01 · An Van Gerven
- Board meeting: 2022-10-19 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: Président du Conseil d'administration, start_date: 2022-10-19 · Frédéric Clais
- Board meeting: 2022-11-16 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: Vice-Présidente, start_date: 2022-11-16 · An Van Gerven
Technical details
{
"facts": [
{
"type": "act_object",
"quote": "Objet de l\u0027acte : Nouveaux repr\u00E9sentants permanents des administrateurs - Nomination pr\u00E9sident et vice-pr\u00E9sident",
"value": "Nouveaux repr\u00E9sentants permanents des administrateurs - Nomination pr\u00E9sident et vice-pr\u00E9sident",
"object": null,
"subject": "e1"
},
{
"date": "2022-11-28",
"type": "filing",
"quote": "Neergelegd/ontvangen op 28 NOV. 2022",
"value": "2022-11-28",
"object": null,
"subject": "e1"
},
{
"date": "2022-08-01",
"type": "permanent_representative",
"quote": "Takeda Belgium S.A. (BE 0403.054.202) a d\u00E9sign\u00E9 comme nouveau repr\u00E9sentant permanent \u00E0 partir du 01/08/2022 Monsieur Michael Nesrallah",
"value": {
"start_date": "2022-08-01"
},
"object": "e2",
"subject": "e3"
},
{
"date": "2022-11-01",
"type": "permanent_representative",
"quote": "Pfizer S.A. (BE 0401.994.823) a d\u00E9sign\u00E9 comme nouveau repr\u00E9sentant permanent \u00E0 partir du 01/11/2022 Madame An Van Gerven",
"value": {
"start_date": "2022-11-01"
},
"object": "e4",
"subject": "e5"
},
{
"date": "2022-10-19",
"type": "board_meeting",
"quote": "REUNION DU CONSEIL D\u0027ADMINISTRATION DU 19 OCTOBRE 2022",
"value": "2022-10-19",
"object": null,
"subject": "e1"
},
{
"date": "2022-10-19",
"type": "officer_appointment",
"quote": "Lors du Conseil d\u0027administration du 19 octobre 2022, Monsieur Fr\u00E9d\u00E9ric Clais a \u00E9t\u00E9 d\u00E9sign\u00E9 comme Pr\u00E9sident du Conseil d\u0027administration.",
"value": {
"role": "Pr\u00E9sident du Conseil d\u0027administration",
"start_date": "2022-10-19"
},
"object": null,
"subject": "e6"
},
{
"date": "2022-11-16",
"type": "board_meeting",
"quote": "REUNION DU CONSEIL D\u0027ADMINISTRATION DU 16 NOVEMBRE 2022",
"value": "2022-11-16",
"object": null,
"subject": "e1"
},
{
"date": "2022-11-16",
"type": "officer_appointment",
"quote": "Lors du Conseil d\u0027administration du 16 novembre 2022, Madame An Van Gerven a \u00E9t\u00E9 d\u00E9sign\u00E9e comme Vice-Pr\u00E9sidente.",
"value": {
"role": "Vice-Pr\u00E9sidente",
"start_date": "2022-11-16"
},
"object": null,
"subject": "e5"
}
],
"act_meta": {
"outcome": "clean",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1899,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "company",
"name": "Association G\u00E9n\u00E9rale de l\u0027Industrie du M\u00E9dicament",
"attrs": {
"seat": "chauss\u00E9e de La Hulpe 166, 1170 Bruxelles",
"legal_form": "Association sans But Lucratif",
"short_name": "AGIM"
}
},
{
"id": "e2",
"kbo": "0403.054.202",
"kind": "company",
"name": "Takeda Belgium S.A.",
"attrs": {}
},
{
"id": "e3",
"kbo": null,
"kind": "person",
"name": "Michael Nesrallah",
"attrs": {
"address": "avenue des Ch\u00EAnes 63, 1180 Uccle",
"birth_date": "1978-11-11",
"birth_place": "Ottawa (Canada)"
}
},
{
"id": "e4",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer S.A.",
"attrs": {}
},
{
"id": "e5",
"kbo": null,
"kind": "person",
"name": "An Van Gerven",
"attrs": {
"address": "Vinkenbosstraat 30, 3053 Haasrode",
"birth_date": "1975-06-10",
"birth_place": "Louvain"
}
},
{
"id": "e6",
"kbo": null,
"kind": "person",
"name": "Fr\u00E9d\u00E9ric Clais",
"attrs": {}
}
]
}11-04-2022 2 directors appointed, 1 resigning
- Michael Nesrallah, Bestuurder
- Paul De Proft, Gedelegeerd bestuurder
- Laurent Henaux, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Laurent Henaux",
"address": null,
"birth_date": null
},
"effective_date": "2022-03-07",
"evidence_quote": "De Aandeelhouder besluit het mandaat van de heer Laurent Henaux als bestuurder van de Vennootschap te herroepen, met ingang van 7 maart 2022."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Michael Nesrallah",
"address": null,
"birth_date": null
},
"effective_date": "2022-03-07",
"evidence_quote": "De Aandeelhouder besluit de heer Michael Nesrallah, houdende de Canadese nationaliteit, keuze van woonplaats doende op de zetel van de Vennootschap te Da Vincilaan 7, 1930 Zaventem, te benoemen als bestuurder van de Vennootschap, met ingang van 7 maart 2022 en voor een termijn van 6 jaar, tot aan de"
},
{
"kind": "director_in",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Paul De Proft",
"address": null,
"birth_date": null
},
"effective_date": "2022-03-07",
"evidence_quote": "De Bestuurders besluiten de heer Paul De Proft, houdende de Belgische nationaliteit en keuze van woonplaats doende op de zetel van de Vennootschap, te Da Vincilaan 7, 1930 Zaventem, te benoemen als gedelegeerd bestuurder van de Vennootschap met ingang van 7 maart 2022."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "NV"
}
}30-04-2021 General meeting · Officer appointment · Officer reappointment · Officer resignation
- Publication: 2021-04-23 · Algemene Vereniging van de Geneesmiddelenindustrie
- Filing: 2021-04-23 · Algemene Vereniging van de Geneesmiddelenindustrie
- General meeting: 2021-03-17 · Algemene Vereniging van de Geneesmiddelenindustrie
- Officer appointment: role: bestuurder, start_date: 2021-03-17 · Takeda Belgium N.V.
- Officer reappointment: role: bestuurder, start_date: 2021-03-17 · AbbVie N.V.
- Officer reappointment: role: bestuurder, start_date: 2021-03-17 · Amgen N.V.
- Officer reappointment: role: bestuurder, start_date: 2021-03-17 · Eli Lilly Benelux N.V.
- Officer reappointment: role: bestuurder, start_date: 2021-03-17 · Pfizer N.V.
- Officer resignation: role: bestuurder, end_date: 2021-03-17 · Merck N.V.
- Permanent representative · Laurerit Henaux
- Officer appointment: role: CEO, belast met het dagelijks bestuur · Caroline Ven
Technical details
{
"facts": [
{
"date": "2021-04-30",
"type": "publication",
"quote": "23 APR. 2021",
"value": "2021-04-23",
"object": null,
"subject": "e1"
},
{
"date": "2021-04-23",
"type": "filing",
"quote": "neergelegd/ontvangen op ... 23 APR. 2021",
"value": "2021-04-23",
"object": null,
"subject": "e1"
},
{
"date": "2021-03-17",
"type": "general_meeting",
"quote": "ALGEMENE VERGADERING VAN 17 MAART 2021",
"value": "2021-03-17",
"object": null,
"subject": "e1"
},
{
"date": "2021-03-17",
"type": "officer_appointment",
"quote": "Benoeming van: 1. Takeda Belgium N.V.",
"value": {
"role": "bestuurder",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e2"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 1. AbbVie N.V.",
"value": {
"role": "bestuurder",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e3"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Herbenoeming van: ... 2. Amgen N.V.",
"value": {
"role": "bestuurder",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e4"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Herbenoeming van: ... 3. Eli Lilly Benelux N.V.",
"value": {
"role": "bestuurder",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e5"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Herbenoeming van: ... 4. Pfizer N.V.",
"value": {
"role": "bestuurder",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e6"
},
{
"type": "officer_resignation",
"quote": "Ontslag van: 1. Merck N.V.",
"value": {
"role": "bestuurder",
"end_date": "2021-03-17"
},
"object": "e1",
"subject": "e7"
},
{
"type": "permanent_representative",
"quote": "Takeda Belgium NV heeft als vaste vertegenwoordiger de heer Laurerit Henaux",
"value": null,
"object": "e2",
"subject": "e8"
},
{
"type": "officer_appointment",
"quote": "Caroline Ven CEO, belast met het dagelijks bestuur",
"value": {
"role": "CEO, belast met het dagelijks bestuur"
},
"object": "e1",
"subject": "e9"
}
],
"act_meta": {
"outcome": "review",
"postfix": [
"publication date 2021-04-23 -\u003E edition 2021-04-30"
],
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1820,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "company",
"name": "Algemene Vereniging van de Geneesmiddelenindustrie",
"attrs": {
"seat": "Terhulpsesteenweg 166, 1170 Brussel",
"legal_form": "Vereniging zonder Winstoogmerk",
"short_name": "AVGI"
}
},
{
"id": "e2",
"kbo": "0403.054.202",
"kind": "company",
"name": "Takeda Belgium N.V.",
"attrs": {
"seat": "Leonardo Da Vincilaan 7, 1930 Zaventem"
}
},
{
"id": "e3",
"kbo": "0845.096.860",
"kind": "company",
"name": "AbbVie N.V.",
"attrs": {
"seat": "avenue Einstein 14, 1300 Wavre"
}
},
{
"id": "e4",
"kbo": "0439.652.401",
"kind": "company",
"name": "Amgen N.V.",
"attrs": {
"seat": "Telecomlaan 5-7, 1831 Diegem"
}
},
{
"id": "e5",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux N.V.",
"attrs": {
"seat": "Markiesstraat 1, 1000 Brussel"
}
},
{
"id": "e6",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer N.V.",
"attrs": {
"seat": "Pleinlaan 17, 1050 Elsene"
}
},
{
"id": "e7",
"kbo": "0403.047.965",
"kind": "company",
"name": "Merck N.V.",
"attrs": {
"seat": "Brusselsesteenweg 288, 3090 Overijse"
}
},
{
"id": "e8",
"kbo": null,
"flag": "Name \u0027Laurerit\u0027 appears to be an OCR error for \u0027Laurent\u0027, but preserved as printed.",
"kind": "person",
"name": "Laurerit Henaux",
"attrs": {
"address": "avenue des B\u00E9cassines 26, 1160 Brussel",
"birth_date": "1966-04-27",
"birth_place": "Toulouse (Frankrijk)"
}
},
{
"id": "e9",
"kbo": null,
"kind": "person",
"name": "Caroline Ven",
"attrs": {
"role": "CEO, belast met het dagelijks bestuur"
}
}
]
}30-04-2021 General meeting · Officer appointment · Officer reappointment · Officer resignation
- Publication: 2021-01-01 · Association Générale de l'Industrie du Médicament
- Filing: 2021-04-23 · Association Générale de l'Industrie du Médicament
- General meeting: 2021-03-17 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: administrateur, start_date: 2021-03-17 · Takeda Belgium S.A.
- Officer reappointment: role: administrateur, start_date: 2021-03-17 · AbbVie S.A.
- Officer reappointment: role: administrateur, start_date: 2021-03-17 · Amgen S.A.
- Officer reappointment: role: administrateur, start_date: 2021-03-17 · Eli Lilly Benelux S.A.
- Officer reappointment: role: administrateur, start_date: 2021-03-17 · Pfizer S.A.
- Officer resignation: date: 2021-03-17, role: administrateur · Merck S.A.
- Permanent representative · Laurent Henaux
Technical details
{
"facts": [
{
"date": "2021-04-30",
"type": "publication",
"quote": "1/2021",
"value": "2021-01-01",
"object": null,
"subject": "e1"
},
{
"date": "2021-04-23",
"type": "filing",
"quote": "neergelegd/ontvangen op 23 APR. 2021",
"value": "2021-04-23",
"object": null,
"subject": "e1"
},
{
"date": "2021-03-17",
"type": "general_meeting",
"quote": "ASSEMBLEE GENERALE DU 17 MARS 2021",
"value": "2021-03-17",
"object": null,
"subject": "e1"
},
{
"date": "2021-03-17",
"type": "officer_appointment",
"quote": "Nomination de: 1. Takeda Belgium S.A.",
"value": {
"role": "administrateur",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e2"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 1. AbbVie S.A.",
"value": {
"role": "administrateur",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e3"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 2. Amgen S.A.",
"value": {
"role": "administrateur",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e4"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 3. Eli Lilly Benelux S.A.",
"value": {
"role": "administrateur",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e5"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 4. Pfizer S.A.",
"value": {
"role": "administrateur",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e6"
},
{
"date": "2021-03-17",
"type": "officer_resignation",
"quote": "D\u00E9mission de : 1. Merck S.A.",
"value": {
"date": "2021-03-17",
"role": "administrateur"
},
"object": "e1",
"subject": "e7"
},
{
"type": "permanent_representative",
"quote": "Takeda Belgium a d\u00E9sign\u00E9 comme repr\u00E9sentant permanent Monsieur Laurent Henaux",
"value": null,
"object": "e2",
"subject": "e8"
}
],
"act_meta": {
"outcome": "review",
"postfix": [
"publication date 2021-01-01 -\u003E edition 2021-04-30"
],
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1896,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "org",
"name": "Association G\u00E9n\u00E9rale de l\u0027Industrie du M\u00E9dicament",
"attrs": {
"seat": "chauss\u00E9e de La Hulpe 166, 1170 Bruxelles",
"legal_form": "Association sans But Lucratif",
"short_name": "AGIM"
}
},
{
"id": "e2",
"kbo": "0403.054.202",
"kind": "company",
"name": "Takeda Belgium S.A.",
"attrs": {
"seat": "Leonardo Da Vincilaan 7, 1930 Zaventem"
}
},
{
"id": "e3",
"kbo": "0845.096.860",
"kind": "company",
"name": "AbbVie S.A.",
"attrs": {
"seat": "avenue Einstein 14, 1300 Wavre"
}
},
{
"id": "e4",
"kbo": "0439.652.401",
"kind": "company",
"name": "Amgen S.A.",
"attrs": {
"seat": "Telecomlaan 5-7, 1831 Diegem"
}
},
{
"id": "e5",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux S.A.",
"attrs": {
"seat": "rue du Marquis 1, 1000 Bruxelles"
}
},
{
"id": "e6",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer S.A.",
"attrs": {
"seat": "boulevard de la Plaine 17, 1050 Ixelles"
}
},
{
"id": "e7",
"kbo": "0403.047.965",
"kind": "company",
"name": "Merck S.A.",
"attrs": {
"seat": "Brusselsesteenweg 288, 3090 Overijse"
}
},
{
"id": "e8",
"kbo": null,
"kind": "person",
"name": "Laurent Henaux",
"attrs": {
"address": "avenue des B\u00E9cassines 26, 1160 Bruxelles",
"birth_date": "1966-04-27",
"birth_place": "Toulouse (France)"
}
},
{
"id": "e9",
"kbo": null,
"kind": "person",
"name": "Caroline Ven",
"attrs": {
"role": "CEO, charg\u00E9 de la gestion journali\u00E8re"
}
}
]
}04-12-2020 Axel Jorion appointed as statutory auditor
- Axel Jorion, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Axel Jorion",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "KPMG Bedrijfsrevisoren CVBA",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "De Aandeelhouder besluit KPMG Bedrijfsrevisoren CVBA, met maatschappelijke zetel te Luchthaven Brussel Nationaal 1K, 1930 Zaventem, vertegenwoordigd door de heer Axel Jorion (IBR Nr. A02363), bedrijfsrevisor, te benoemen tot commissaris van de Vennootschap voor een periode van drie jaar (in het bijz"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "NV"
}
}04-05-2020 Transaction in capital or shares
Technical details
{
"events": [
{
"kind": "share_transfer",
"amount": null,
"currency": null,
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"amount_type": "onbekend",
"effective_date": "2020-04-01",
"evidence_quote": "De vergadering stemt in met de verrichting waarbij de Overnemende Vennootschap de Overgenomen Vennootschap bij wijze van met fusie door overneming gelijkgestelde verrichting overneemt met ingang vanaf 1 april 2020 onmiddellijk na middernacht (tussen 31 maart 2020 en 1 april 2020) om 0u01.",
"contribution_type": null
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "Comm"
}
}13-02-2020 Publication in the Belgian Official Gazette, Miscellaneous
Technical details
{
"stage": "proposal",
"notary": {
"name": "Takeda International Holding GmbH",
"firm_city": null,
"firm_name": null,
"office_city": "Brussel",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2020-02-13",
"filing_date": "2020-02-04",
"act_kind_objet": "Fusievoorstel"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2020-01-29",
"unanimous": null
},
"conversion": null,
"detected_kind": "merger_absorption",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0403.054.202",
"name": "Takeda Belgium CVA",
"role": "acquiring",
"address": "Da Vincilaan 7, 1930 Zaventem",
"is_foreign": false,
"legal_form": "Commanditaire Vennootschap op Aandelen",
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": "0563.700.355",
"name": "Shire Belgium SPRL",
"role": "absorbed",
"address": "rue Montoyer 47, 1000 Brussel",
"is_foreign": false,
"legal_form": "Besloten Vennootschap met Beperkte Aansprakelijkheid",
"is_new_company": false,
"jurisdiction_country": "BE"
}
],
"exchange_ratio": null,
"legal_articles": [
"12:7",
"12:13",
"12:50"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "Het gehele vermogen van Shire Belgium SPRL, inclusief alle rechten en verplichtingen, wordt overgedragen naar Takeda Belgium CVA zonder uitzondering.",
"equity_transferred_eur": null,
"accounting_effective_date": "2020-04-01"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "Takeda Belgium",
"legal_form": "Commanditaire Vennootschap op Aandelen"
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "Takeda International Holding GmbH",
"person_name": null,
"org_rep_person_name": "Peter Stossel"
},
"summary_narrative": "Dit is een voorstel tot een met fusie door overneming gelijkgestelde verrichting tussen Takeda Belgium CVA en Shire Belgium SPRL. De overnemende vennootschap is Takeda Belgium CVA, gevestigd te Zaventem, en de over te nemen vennootschap is Shire Belgium SPRL, gevestigd te Brussel. De verrichting is onderworpen aan goedkeuring door de buitengewone algemene vergaderingen van de vennoten van beide vennootschappen. De fusie zal voor boekhoudkundige doeleinden gelden vanaf 1 april 2020.",
"co_filed_documents": [
"Fusievoorstel"
],
"detected_real_type": "fusion_proposal",
"referenced_correction": null,
"should_reroute_to_category": null
}29-01-2020 1 director appointed, 1 resigning
- STOSSEL Peter, Zaakvoerder
- Takeda Nederland B.V., Zaakvoerder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "zaakvoerder",
"person": {
"rrn": null,
"name": "Takeda Nederland B.V.",
"address": null,
"birth_date": null
},
"effective_date": "2019-12-19",
"evidence_quote": "De vergadering beslist, ingevolge de wijziging van beherende vennoot, de volgende huidige statutaire zaakvoerder te ontslaan, met ingang vanaf heden: de vennootschap naar Nederlands recht \u0022Takeda Nederland B.V.\u0022, vast vertegenwoordigd door de heer OVERKAMP Aarnoud."
},
{
"kind": "director_in",
"role": "zaakvoerder",
"person": {
"rrn": null,
"name": "STOSSEL Peter",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Takeda International Holding GmbH",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2019-12-19",
"evidence_quote": "De vergadering beslist te benoemen als statutaire zaakvoerder, voor onbepaalde duur en met ingang vanaf heden: - de vennootschap naar Zwitsers recht \u0022Takeda International Holding GmbH\u0022, voornoemd, vast vertegenwoordigd door de heer STOSSEL Peter, wonende te H\u00FCrliweidweg 6, 6048 Horw, Zwitserland."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "Comm"
}
}30-07-2019 Capital decrease
Technical details
{
"events": [
{
"kind": "capital_decrease",
"amount": 30013084.49,
"currency": "EUR",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"amount_type": "uitgiftepremie",
"effective_date": "2018-07-17",
"evidence_quote": "De vergadering beslist tot vermindering van de uitgiftepremies, in toepassing van artikel 657 juncto 612 van het Wetboek van vennootschappen, met een bedrag van dertig miljoen dertienduizend vierentachtig euro: negenenveertig cent (\u20AC 30.013.084,49)",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "Comm"
}
}06-02-2019 1 director appointed, 1 resigning
- Laurent Henaux, Zaakvoerder
- Gundula Schneidewind, Zaakvoerder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "zaakvoerder",
"person": {
"rrn": null,
"name": "Gundula Schneidewind",
"address": null,
"birth_date": null
},
"effective_date": "2019-01-08",
"evidence_quote": "De enige zaakvoerder heeft besloten om de bevoegdheden (onder meer voor het dagelijks bestuur) die op 28 september 2017 waren toegekend aan mevrouw Gundula Schneidewind in te trekken met ingang vanaf 8 januari 2019."
},
{
"kind": "director_in",
"role": "zaakvoerder",
"person": {
"rrn": null,
"name": "Laurent Henaux",
"address": null,
"birth_date": null
},
"effective_date": "2019-01-08",
"evidence_quote": "De enige zaakvoerder heeft besloten om de bevoegdheden die waren toegekend aan mevrouw Gundula Schneidewind, waaronder deze van het dagelijks bestuur, toe te kennen aan de heer Laurent Henaux... Het mandaat van de heer Henaux wordt toegekend voor onbepaalde duur en met ingang vanaf 8 januari 2019."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "Comm"
}
}12-12-2017 Change in the board of directors
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "Comm"
}
}03-11-2017 Axel Jorion reappointed as statutory auditor
- Axel Jorion, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_renew",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Axel Jorion",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "KPMG Bedrijfsrevisoren Burg. CVBA",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "De algemene vergadering herbenoemt KPMG Bedrijfsrevisoren Burg. CVBA (B00001), Bourgetlaan 40 te 1130 Brussel, als commissaris voor een termijn van 3 jaren."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "Comm"
}
}23-10-2017 Change in the board of directors
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "Comm"
}
}11-07-2017 Change in the board of directors
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "Comm"
}
}11-05-2017 Aarnoud OVERKAMP reappointed as manager
- Aarnoud OVERKAMP, Zaakvoerder
Technical details
{
"events": [
{
"kind": "director_renew",
"role": "zaakvoerder",
"person": {
"rrn": null,
"name": "Aarnoud OVERKAMP",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0403054202",
"name": "TAKEDA NEDERLAND B.V.",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2017-05-01",
"evidence_quote": "TAKEDA NEDERLAND B.V., met zetel te Jupiterstraat 250, 2132 HK Hoofddorp, Nederland, ingeschreven in de Kamer van Koophandel onder nummer 34035387, wordt met ingang van 1 mei 2017, in de uitoefening van haar mandaat als zaakvoerder van TAKEDA BELGIUM CVA, vast vertegenwoordigd door de heer Aarnoud O"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "Comm"
}
}27-09-2016 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2016-09-15",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA BELGIUM",
"legal_form": "Comm"
},
"signature_regime": null,
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}27-09-2016 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": true,
"seat_change": false,
"object_change": true,
"effective_date": "2016-09-01",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA CHRISTIAENS",
"legal_form": "SCA"
},
"signature_regime": null,
"special_mandates": [
{
"quote": "Tous pouvoirs ont \u00E9t\u00E9 conf\u00E9r\u00E9s \u00E0 monsieur Filip Van Acoleyen, monsieur Jan De Poorter, monsieur Maxime Schurmans, madame Vicki Kaluza et madame Jenna Van Isterdael, collaborateurs du cabinet d\u0027avocats Laga SCRL, \u00E0 1831 Diegem, Berkenlaan 8a, chacun agissant s\u00E9par\u00E9ment, avec droit de substitution, ... afin d\u0027assurer les formalit\u00E9s aupr\u00E8s d\u0027un guichet d\u0027entreprise en vue d\u0027assurer l\u0027inscription/la modification des donn\u00E9es dans la Banque Carrefour des Entreprises et, le cas \u00E9ch\u00E9ant, aupr\u00E8s de l\u0027Administration de la Taxe sur la Valeur Ajout\u00E9e.",
"holder_kbo": null,
"holder_name": "Laga SCRL",
"scope_categories": [
"KBO",
"tax",
"filing"
],
"with_substitution": true
},
{
"quote": "Tous pouvoirs ont \u00E9t\u00E9 conf\u00E9r\u00E9s \u00E0 ... monsieur Lucas Y\u00FCksel et monsieur Bob Maurau, collaborateurs de Deloitte Conseils Fiscaux SCRL, \u00E0 1831 Diegem, Berkenlaan 8a, chacun agissant s\u00E9par\u00E9ment, avec drolt de substitution, afin d\u0027assurer les formalit\u00E9s aupr\u00E8s d\u0027un guichet d\u0027entreprise en vue d\u0027assurer l\u0027inscription/la modification des donn\u00E9es dans la Banque Carrefour des Entreprises et, le cas \u00E9ch\u00E9ant, aupr\u00E8s de l\u0027Administration de la Taxe sur la Valeur Ajout\u00E9e.",
"holder_kbo": null,
"holder_name": "Deloitte Conseils Fiscaux SCRL",
"scope_categories": [
"KBO",
"tax",
"filing"
],
"with_substitution": true
}
],
"governance_change": {
"admin_delegated_added": []
}
}13-07-2016 Publication in the Belgian Official Gazette, Miscellaneous
Technical details
{
"stage": "proposal",
"notary": {
"name": "Maxime Schurmans",
"firm_city": null,
"firm_name": null,
"office_city": "Diegem",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2016-07-13",
"filing_date": "2016-06-21",
"act_kind_objet": "D\u00E9p\u00F4t d\u0027un projet de fusion conform\u00E9ment \u00E0 l\u0027article 676 juncto les articles"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2016-06-21",
"unanimous": null
},
"conversion": null,
"detected_kind": "merger_absorption",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0403.054.202",
"name": "TAKEDA CHRISTIAENS",
"role": "acquiring",
"address": "Chauss\u00E9e de Gand 615, 1080 Molenbeek-Saint-Jean",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 en commandite par action",
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": "0448.691.613",
"name": "TAKEDA BELGIUM",
"role": "absorbed",
"address": "Chauss\u00E9e de Gand 615, 1080 Molenbeek-Saint-Jean",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 en commandite par action",
"is_new_company": false,
"jurisdiction_country": "BE"
}
],
"exchange_ratio": null,
"legal_articles": [
"676",
"719",
"720",
"721",
"722",
"723",
"724",
"725",
"726",
"727"
],
"is_cross_border": false,
"is_silent_merger": true,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "L\u0027ensemble du patrimoine, tant les droits que les obligations, de Takeda Belgium est transf\u00E9r\u00E9 \u00E0 Takeda Christiaens. Le transfert concerne l\u0027ensemble des actifs et passifs de la soci\u00E9t\u00E9 absorb\u00E9e, y compris ses activit\u00E9s pharmaceutiques et chimiques.",
"equity_transferred_eur": null,
"accounting_effective_date": "2016-04-01"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA CHRISTIAENS",
"legal_form": "Soci\u00E9t\u00E9 en commandite par action"
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "Laga",
"person_name": null,
"org_rep_person_name": "Maxime Schurmans"
},
"summary_narrative": "Le pr\u00E9sent document est un projet de fusion assimil\u00E9e \u00E0 une fusion par absorption, \u00E9tabli conform\u00E9ment aux articles 676 et suivants du Code des soci\u00E9t\u00E9s belges. Takeda Christiaens, soci\u00E9t\u00E9 en commandite par action, entend absorber Takeda Belgium, \u00E9galement soci\u00E9t\u00E9 en commandite par action, en transf\u00E9rant l\u0027int\u00E9gralit\u00E9 de son patrimoine. La fusion est conditionn\u00E9e au transfert pr\u00E9alable de toutes les actions de Takeda Belgium \u00E0 Takeda Christiaens, qui deviendra titulaire de 100 % du capital. L\u0027op\u00E9ration, soumise \u00E0 l\u0027approbation des assembl\u00E9es g\u00E9n\u00E9rales extraordinaires, produira ses effets jurid",
"co_filed_documents": [
"Projet de fusion en date du 21 juin 2016"
],
"detected_real_type": "fusion_proposal",
"referenced_correction": null,
"should_reroute_to_category": null
}13-07-2016 Publication in the Belgian Official Gazette, Miscellaneous
Technical details
{
"stage": "proposal",
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2016-07-13",
"filing_date": "2016-06-21",
"act_kind_objet": "D\u00E9p\u00F4t d\u0027un projet de fusion conform\u00E9ment \u00E0 l\u0027article 676 juncto les articles"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2016-06-21",
"unanimous": null
},
"conversion": null,
"detected_kind": "merger_absorption",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0403.054.202",
"name": "Takeda Christiaens",
"role": "acquiring",
"address": "Chauss\u00E9e de Gand 615, 1080 Molenbeek-Saint-Jean",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 en Commandite par Action",
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": "0478.867.422",
"name": "Nyco Holdings Belgium",
"role": "absorbed",
"address": "Chauss\u00E9e de Gand 615, 1080 Molenbeek-Saint-Jean",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e",
"is_new_company": false,
"jurisdiction_country": "BE"
}
],
"exchange_ratio": null,
"legal_articles": [
"676",
"719",
"720",
"721",
"722",
"723",
"724",
"725",
"726",
"727"
],
"is_cross_border": false,
"is_silent_merger": true,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "L\u0027ensemble du patrimoine, tant les droits que les obligations, de Nyco Holdings Belgium est transf\u00E9r\u00E9 \u00E0 Takeda Christiaens. Aucun bien immobilier n\u0027est inclus dans le transfert.",
"equity_transferred_eur": null,
"accounting_effective_date": "2016-04-01"
},
"subject_company": {
"kbo": "0403.054.202",
"name_full": "TAKEDA CHRISTIAENS",
"legal_form": "Soci\u00E9t\u00E9 en Commandite par Action"
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "Laga",
"person_name": null,
"org_rep_person_name": "Maxime Schurmans"
},
"summary_narrative": "Le pr\u00E9sent document est un projet de fusion assimil\u00E9e \u00E0 une fusion par absorption, soumis \u00E0 l\u0027approbation des assembl\u00E9es g\u00E9n\u00E9rales extraordinaires des associ\u00E9s de Takeda Christiaens et de Nyco Holdings Belgium. La fusion est conditionn\u00E9e par le transfert pr\u00E9alable de toutes les actions de Nyco Holdings Belgium \u00E0 Takeda Christiaens, qui deviendra ainsi titulaire de 100 % du capital. L\u0027op\u00E9ration, pr\u00E9vue pour produire ses effets juridiques \u00E0 partir du 1er septembre 2016, entra\u00EEne la disparition de Nyco Holdings Belgium et le transfert int\u00E9gral de son patrimoine \u00E0 Takeda Christiaens. Le projet a \u00E9",
"co_filed_documents": [
"Projet de fusion en date du 21 juin 2016"
],
"detected_real_type": "fusion_proposal",
"referenced_correction": null,
"should_reroute_to_category": null
}| Legal name | TAKEDA BELGIUM |